Healthcare
ByAstraZeneca Reports 2025 Performance with Strong Brand Momentum Across Core Therapeutic Areas
AstraZeneca today announced its full-year 2025 results, reflecting continued growth across oncology, cardiovascular-renal-metabolism (CVRM), respiratory & immunology, and…
GSK Reports Full-Year 2025 Results with Strategic Portfolio Focus
GSK today reported its full-year performance for 2025 and outlined its strategic approach to long-term growth across vaccines,…
Roche Reports Full-Year 2025 Results and Provides Strategic Portfolio Insights
Roche today announced its full-year 2025 performance and outlined its strategic positioning across key therapeutic areas. Roche maintained…
Top 10 Pharma Brands of 2025 — Sales Performance, Company Strategy & Market Outlook
The pharmaceutical market in 2025 was defined by high-value specialty brands delivering breakthrough outcomes in oncology, metabolic disease,…
How Does Roche’s TA-Wise Fortress Strategy Conquer 2030 LOE Cliffs Amid Obesity Wars?
Roche orchestrates a pharma-diagnostics juggernaut, surgically allocating 60% of R&D across five therapeutic arenas while weaponizing FoundationOne/Flatiron (covering 60% of pipeline…
What Drives Novartis’ Pipeline Dominance Through 2030?
Novartis’ clinical pipeline exemplifies a “focus factory” strategy, ruthlessly prioritizing 30+ high-ROI NMEs across five core areas (immunology,…
